Although numerous somatic mutations have been identified in IDH1/2 in tumors [691,692], there appears to be a predilection for specific binding site “hotspot” mutations (Arg 132 for IDH1, Arg 172 for IDH2) in certain diseases such as leukemia and glioma. Here, IDH2 is linked to glioma.